Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. CI
stocks logo

CI

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
62.62B
+3.55%
7.121
+5.96%
64.22B
+0.82%
7.919
+5.45%
65.76B
+0.11%
7.940
+19.58%
Estimates Revision
The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by -1.89%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.95%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.1%
In Past 3 Month
Stock Price
Go Down
down Image
-1.89%
In Past 3 Month
20 Analyst Rating
up Image0
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 380.79 USD with a low forecast of 341.00 USD and a high forecast of 407.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
4 Hold
0 Sell
Strong Buy
up Image0
Current: 314.350
sliders
Low
341.00
Averages
380.79
High
407.00
up Image0
Current: 314.350
sliders
Low
341.00
Averages
380.79
High
407.00
Barclays
Overweight
maintain
$382 -> $385
2025-06-02
Reason
Barclays
Price Target
$382 -> $385
2025-06-02
maintain
Overweight
Reason
Barclays raised the firm's price target on Cigna to $385 from $382 and keeps an Overweight rating on the shares. Following Q1 earnings and "several negative data points" around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Guggenheim
Guggenheim
Buy
maintain
$928 -> $936
2025-05-23
Reason
Guggenheim
Guggenheim
Price Target
$928 -> $936
2025-05-23
maintain
Buy
Reason
Guggenheim raised the firm's price target on Eli Lilly (LLY) to $936 from $928 and keeps a Buy rating on the shares after detailing how the firm is thinking about GLP1 market dynamics through the remainder of the year. Both Lilly and Novo Nordisk (NVO) have stated their strong preference for open access and the firm notes as part of the updated agreement with Express Scripts and Cigna's (CI) Evernorth announced Wednesday that the companies maintained open access through the end of 2026 for Wegovy and Zepbound with prices "in line with Lilly's normal price concessions," per the company. Overall, the firm believes both companies are positioned to meet 2025 guidance, although it continues to assume Novo will be at the low end of guidance with material risk to sales and earnings in 2026-27 if GLP1 prescriptions don't accelerate.
Citi
Sell
maintain
$30
2025-05-22
Reason
Citi
Price Target
$30
2025-05-22
maintain
Sell
Reason
Citi keeps a Sell rating on Hims & Hers (HIMS) with a $30 price target after Cigna's (CI) Evernorth announced it is launching a new benefit option that caps patient out-of-pocket costs for Wegovy and Zepbound at $200 per month. This is lower than the cash pay price for Wegovy offered through NovoCare and Tirzepatide Vials offered through LillyDirect, the analyst tells investors in a research note. Citi says the Evernorth's offering also has the benefit of counting out-of-pocket costs towards the patients' annual deductible and simplifying prior authorization. The firm believes this will be a "slight headwind" to Hims & Hers' newly announced NovoCare partnership where patients get access to Wegovy and ongoing clinician and nutritional support for as little as $599 per month. The direct-to-consumer platforms have benefited from employer reluctance to cover GLP-1s for weight loss due to prohibitive costs, but Evernorth's offering may accelerate employer coverage adoption, contends Citi.
Truist
David MacDonald
Buy
maintain
$385 -> $405
2025-05-12
Reason
Truist
David MacDonald
Price Target
$385 -> $405
2025-05-12
maintain
Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Cigna to $405 from $385 and keeps a Buy rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Baird
Michael Ha
Buy
Maintains
$388 → $362
2025-04-15
Reason
Baird
Michael Ha
Price Target
$388 → $362
2025-04-15
Maintains
Buy
Reason
Truist Securities
David Macdonald
Strong Buy
Maintains
$375 → $385
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$375 → $385
2025-04-11
Maintains
Strong Buy
Reason
Truist raised the firm's price target on Cigna to $385 from $375 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cigna Group (CI.N) is 10.10, compared to its 5-year average forward P/E of 10.92. For a more detailed relative valuation and DCF analysis to assess Cigna Group 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
10.92
Current PE
10.10
Overvalued PE
11.97
Undervalued PE
9.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
9.18
Current EV/EBITDA
8.19
Overvalued EV/EBITDA
9.94
Undervalued EV/EBITDA
8.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
0.42
Current PS
0.32
Overvalued PS
0.47
Undervalued PS
0.37

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

CI News & Events

Events Timeline

(ET)
2025-06-20
12:19:14
Health insurers to promise improved pre-approval process, WSJ reports
select
link
2025-06-16 (ET)
2025-06-16
16:31:35
Senate Republicans abandon Medicare cost cuts, Bloomberg reports
select
2025-06-05 (ET)
2025-06-05
14:06:21
Senate Republicans consider Medicare spending cuts, Bloomberg says
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.0
06-21WSJ
Exclusive | Health Insurers to Promise Changes to Preapproval Process That Drew Backlash
  • Health Insurers' Response: In light of backlash following the murder of a top executive, health insurers are planning to implement measures aimed at improving the preapproval process for care access.

  • Upcoming Initiative Announcement: The details of this initiative are expected to be revealed early next week by industry insiders.

Preview
7.0
06-20Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
  • Healthcare Debate: A public dispute over U.S. drug pricing has emerged between billionaire Mark Cuban and Senator Elizabeth Warren, focusing on the role of Pharmacy Benefit Managers (PBMs) versus pharmaceutical companies in driving up costs.

  • Cuban's Critique: Cuban argues that PBMs are the main contributors to inflated drug prices due to their control over formularies and rebate negotiations, while Warren blames major pharmaceutical firms for exploiting tax loopholes to avoid paying federal taxes.

Preview
8.0
06-18NASDAQ.COM
Interesting CI Put And Call Options For August 15th
  • Put Contract Analysis: The $310.00 put contract offers a premium of $11.20, allowing investors to potentially buy shares at an effective cost basis of $298.80, which is attractive compared to the current price of $314.52. There is a 59% chance that the contract may expire worthless, yielding a return of 3.61% on cash commitment.

  • Call Contract Overview: The $320.00 call contract has a premium of $12.40, providing a potential total return of 5.68% if the stock is called away by expiration. With a 52% chance of expiring worthless, this could yield an additional 3.94% return for investors who retain their shares.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cigna Group (CI) stock price today?

The current price of CI is 314.35 USD — it has decreased -0.02 % in the last trading day.

arrow icon

What is Cigna Group (CI)'s business?

The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.

arrow icon

What is the price predicton of CI Stock?

Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 380.79 USD with a low forecast of 341.00 USD and a high forecast of 407.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cigna Group (CI)'s revenue for the last quarter?

Cigna Group revenue for the last quarter amounts to 65.50B USD, increased 14.40 % YoY.

arrow icon

What is Cigna Group (CI)'s earnings per share (EPS) for the last quarter?

Cigna Group. EPS for the last quarter amounts to 4.85 USD, decreased -600.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cigna Group (CI)'s fundamentals?

The market is revising Upward the revenue expectations for The Cigna Group (CI) for FY2025, with the revenue forecasts being adjusted by 1.95% over the past three months. During the same period, the stock price has changed by -1.89%.
arrow icon

How many employees does Cigna Group (CI). have?

Cigna Group (CI) has 73500 emplpoyees as of June 23 2025.

arrow icon

What is Cigna Group (CI) market cap?

Today CI has the market capitalization of 83.98B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free